Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

Lund University28 enrolled

Overview

The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon counterregulatory response to hypoglycemia in type 1 diabetes.

Vildagliptin (50 mg BID) or placebo is given as add-on to insulin treatment for four weeks in patients with type 1 diabetes. Then, a hypoglycemic clamp (2.5 mmol/l glucose) is undertaken with the determination of glucagon.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Diabetes Hypoglycemia

Interventions

VildagliptinDRUG

Vildagliptin (50 mg BID) in four weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 1 diabetes * Age \>18 years * HbA1c 6.5-8,5% Exclusion Criteria: * Pregnancy * Lactation * Acute infection * Liver disease * Treatment with cortisol

Locations (1)

Department of Clinical Sciences Lund, Lund University

Lund, Sweden

Outcomes

Primary Outcomes

Glucagon response to hypoglycemia

Change in glucagon from before hypoglycemic clamp until after 45 min

Time frame: 45 min

Secondary Outcomes

Catecholamine response to hypoglycemic

Change in catecholamines from before hypolycemic clamp to 45 min

Time frame: 45 min

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.